Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (401-410 of 580) with videos related to

Pageof 58
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxelKeith T Flaherty, Joan Schiller, Lynn M Schuchter, et al.
The Journal of Experimental Medicine|April 29, 2017
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibitionHelen L Young, Emily J Rowling, Mattia Bugatti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB TrialXinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Plos One|March 8, 2014
An active learning approach for rapid characterization of endothelial cells in human tumorsRaghav K Padmanabhan, Vinay H Somasundar, Sandra D Griffith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Innovations and challenges in melanoma: summary statement from the first Cambridge conferenceMichael B Atkins, David E Elder, Richard Essner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant MelanomaReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Pigment Cell & Melanoma Research|August 8, 2009
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008Sanjiv S Agarwala, Jurgen C Becker, Alexander M Eggermont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Pageof 58

Showing results (401-410 of 580) with videos related to

Sort By:
Pageof 58
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxelKeith T Flaherty, Joan Schiller, Lynn M Schuchter, et al.
The Journal of Experimental Medicine|April 29, 2017
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibitionHelen L Young, Emily J Rowling, Mattia Bugatti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB TrialXinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Plos One|March 8, 2014
An active learning approach for rapid characterization of endothelial cells in human tumorsRaghav K Padmanabhan, Vinay H Somasundar, Sandra D Griffith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Innovations and challenges in melanoma: summary statement from the first Cambridge conferenceMichael B Atkins, David E Elder, Richard Essner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant MelanomaReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Pigment Cell & Melanoma Research|August 8, 2009
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008Sanjiv S Agarwala, Jurgen C Becker, Alexander M Eggermont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Future Oncology (London, England)|June 13, 2023
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Pageof 58